Ophthalmic Topical Beta Blockers: Review of Ocular and Systemic Adverse Effects

References

• Zimmerman T.J., Kaufman H.R. Timolol: A beta-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol. 1977; 95: 601–604
   PubMed Web of Science ®Google Scholar
• McMahon C.D., Shaffer R.N., Hoskins H.D., Hetherington J. Adverse effects experienced by patients taking Timolol. Am. J. Ophthalmol. 1979; 88: 736–738
   PubMed Web of Science ®Google Scholar
• Van Buskirk E.M. Adverse reactions from Timolol administration. Ophthalmology 1987; 87: 447–450
   Google Scholar
• Phillips C.I., Howitt G., Rowlands D.J. Propranolol as an ocular hypotensive agent. Br. J. Ophthalmol. 1967; 51: 222–226
   PubMed Web of Science ®Google Scholar
• Wilson R.P., Spaeth G.L., Poryzees E. The place of Timolol in the practice of ophthalmology. Ophthalmology 1980; 87: 451–454
   PubMed Web of Science ®Google Scholar
• Boger W.P., Puliafito C.A., Steinert R.F., Langston D.P. Long term experience with Timolol ophthalmic solution in patients with open angle glaucoma. Ophthalmology 1978; 85: 259–267
   PubMed Web of Science ®Google Scholar
• Merte H.J., Merkle W. Results of longterm treatment of glaucoma with Timolol ophthalmic solution. Klin. Monatsbl. Augenheilkd. 1980; 177: 562–571
   PubMed Web of Science ®Google Scholar
• Steinert R.F., Thomas J.V., Boger W.P. Long term drift and continued efficacy after multi-year Timolol therapy. Arch. Ophthalmol. 1981; 99: 100–103
   PubMed Web of Science ®Google Scholar
• Zimmerman T.J., Leader B.J., Golob D.S. Potential side effects of Timolol therapy in the treatment of glaucoma. Ann. Ophthalmol. 1981; 13: 683–689
   PubMed Web of Science ®Google Scholar
• Fraunfelder F.T. Ocular beta-blockers and systemic effects. Arch. Intern. Med. 1986; 146: 1073–1074
   PubMed Web of Science ®Google Scholar
• Berrospi A.R., Leibowitz H.W. Betaxolol: A new beta-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol. 1982; 100: 943–946
   PubMed Web of Science ®Google Scholar
• Kitazawa Y., Azuma I., Takase M., Komemushi S. Ocular hypotensive effects of carteolol hydrochloride in primary open angle glaucoma and ocular hypertensive patients. Nippon Ganka Gakkai Zasshi 1981; 85: 798–804
   PubMedGoogle Scholar
• Merte H.J., Mertz M., Stryz J. Augendruck unter Metipranolol—einwirkurg. Medikamen-rose Glaukomtherapie, G.K. Krieglstein, W. Leydhecker. J. F. Bergmann, Munich 1982; 189–193
   Google Scholar
• The Levobunolol Study Group. Levobunolol: A beta-adrenergic antagonist effective in longterm treatment of glaucoma. Ophthalmology 1985; 92: 1271–1276
   PubMed Web of Science ®Google Scholar
• Andreasson S., Moeller-Jensen K. Effect of Pindolol on intra-ocular pressure in glaucoma: Pilot study and a randomized comparison with Timolol. Br. J. Ophthalmol. 1983; 67: 228–230
   PubMed Web of Science ®Google Scholar
• Kitazawa Y., Horie T., Shirato S. Ocular and systemic effects of new beta-blocking agents Carteolol and Befunolol. Medikamentose Glaukomtherapie, G.K. Krieglstein, W. Leydhecker. J. F. Bergmann, Munich 1982; 183–187
   Google Scholar
• Forbes M. Influence of miotics on visual fields in glaucoma. Invest. Ophthalmol. 1966; 5: 139
   Google Scholar
• Abramson D.H., Franzen L.R., Coleman D.J. Pilocarpine in the presbyope: Demonstration of an effect on the anterior chamber and lens thickness. Arch. Ophthalmol. 1973; 89: 100
   PubMed Web of Science ®Google Scholar
• Epstein E., Kaufman I. Systemic Pilocarpine toxicity from overdosage. Am. J. Ophthalmol. 1965; 59: 109
   PubMed Web of Science ®Google Scholar
• Shaffer R.N., Hetherington J. Anti-cholinesterase drugs and cataracts. Am. J. Ophthalmol. 1966; 62: 613
   PubMed Web of Science ®Google Scholar
• Westsmith R.A., Abernethy R.E. Detachment of retina with use of diisopropyl fluorophosphate (Fluropryl) in treatment of glaucoma. Arch. Ophthalmol. 1954; 52: 779
   Web of Science ®Google Scholar
• Ellis P.P. systemic effects of locally applied anticholinesterase agents. Invest. Ophthalmol. 1966; 5: 146
   Google Scholar
• Drance S.M., Ross R.A. The ocular effects of epinephrine. Surv. Ophthalmol. 1982; 26: 207
   PubMedGoogle Scholar
• Aronson A.B., Sassetti R. Experimental ocular hypersensitivity to polyepinephrine and its analogs. Invest. Ophthalmol. 1970; 9: 12
   PubMedGoogle Scholar
• Byron H.M. Conjunctival reaction due to L-epinephrine bitartrate (Epitrate). Arch. Ophthalmol. 1960; 63: 567
   PubMed Web of Science ®Google Scholar
• Corin M.E., Spencer W.H. Conjunctival melanin deposits: A side effect of topical epinephrine therapy. Arch. Ophthalmol. 1963; 69: 317
   PubMed Web of Science ®Google Scholar
• Reinecke R.D., Kuwabara T. Corneal deposits secondary to topical epinephrine. Arch. Ophthalmol. 1963; 70: 170
   PubMed Web of Science ®Google Scholar
• Miller D., Brooks S.M., Mobilia E. Adrenochrome staining of soft contact lenses. Ann. Ophthalmol. 1976; 8: 65
   PubMedGoogle Scholar
• Michels R.G., Maumanee A.E. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am. J. Ophthalmol. 1975; 80: 379
   PubMed Web of Science ®Google Scholar
• McReynolds W.U., Havener W.H., Henderson J.W. Hazards of the use of sympathomimetic drugs in ophthalmology. Arch. Ophthalmol. 1956; 56: 176
   Web of Science ®Google Scholar
• Lansche R.K. Systemic reactions to topical epinephrine and phenylephrine. Am. J. Ophthalmol. 1966; 61: 95
   PubMed Web of Science ®Google Scholar
• Flach A.J. Ophthalmic clinical pharmacology review: Epinephrine and the therapy of the glaucoma. J. Toxicol. Cut. Ocular Toxicol. 1984; 3(1)31–51
   Web of Science ®Google Scholar
• Lichter P.R., Newman L.P., Wheeler N.C., Beall O.V. Patient tolerance to carbonic anhydrase inhibitors. Am. J. Ophthalmol. 1978; 85: 495
   PubMed Web of Science ®Google Scholar
• Kass M.S., Kolker A.E., Gordon M., Goldberg I., Gieser D.K., Krupin T., Becker B. Acetozolamide and urolithiasis. Ophthalmology 1981; 88: 261
   PubMed Web of Science ®Google Scholar
• Werblin T.P., Pollack I.P., Liss R.A. Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology 1980; 87: 350
   PubMed Web of Science ®Google Scholar
• Ahlquist R.P. A study of adrenotropic receptors. Am. J. Physiol. 1948; 142: 586–589
   Google Scholar
• Lands A.M., Arnold A., McAuliff J.P., Ludnena F.P., Brown T.G. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–598
   PubMed Web of Science ®Google Scholar
• Coakes R.L., Brubaker R.F. The mechanism of action of Timolol in lowering intra-ocular pressure. Arch. Ophthalmol. 1978; 96: 2045–2053
   PubMed Web of Science ®Google Scholar
• Sears M.L. Regulation of aqueous flow by the adenylate cyclase receptor complex in ciliary epithelium. Am. J. Ophthalmol. 1985; 100: 194–198
   PubMed Web of Science ®Google Scholar
• Mills K.B. The role of beta-blockers in glaucoma. Res. Clin. Forum. 1987; 9: 87–91
   Google Scholar
• Allen R.C., Hertzmark E., Walker A.M., Epstein D.L. A double masked comparison of Betaxolol versus Timolol in the tretment of open angle glaucoma. Am. J. Ophthalmol. 1986; 101: 535–541
   PubMed Web of Science ®Google Scholar
• Duff G.R., Newcombe R.C. The twelve hour control of intraocular pressure on Carteolol 2% twice daily. Br. J. Ophthalmol. 1988; 72: 890–891
   PubMed Web of Science ®Google Scholar
• Krieglstein G.K. Beta blocker—therapie der Glaukoma. Medikamentose Glaukomtherapie, G.K. Krieglstein, W. Leydhecker. J. F. Bergmann, Munich 1982; 29–40
   Google Scholar
• Van Buskirk E.M. Corneal anesthesia after Timolol maleate therapy. Am. J. Ophthalmol. 1979; 88: 739–743
   PubMed Web of Science ®Google Scholar
• Bonomi L., Zavarise G., Noya E. Effects of Timolol maleate on tear flow in human eyes. Graefes Arch. Klin. Exp. Ophthalmol. 1980; 213: 19–22
   Google Scholar
• Scoville B., Mueller B., White B.G., Krieglstein G.K. A double masked comparison of Carteolol and Timolol in ocular hypertension. Am. J. Ophthalmol. 1988; 105: 150–154
   PubMed Web of Science ®Google Scholar
• Kruse W. Metipranolol—ein neuer beta rezeptoren blocker. Klin. Monatsbl. Augenheilkd. 1983; 182: 582–584
   PubMedGoogle Scholar
• Berry D.P., Van Buskirk E.M., Shields M.B. Betaxolol and Timolol: A comparison of efficacy and side effects. Arch. Ophthalmol. 1984; 102: 42–45
   PubMed Web of Science ®Google Scholar
• Boger W.P., Steinert R.F., Puliafito C.A., Langston D.P. Clinical trial comparing Timolol ophthalmic solution to Pilocarpine in open angle glaucoma. Am. J. Ophthalmol. 1978; 86: 8
   PubMed Web of Science ®Google Scholar
• Radius R.L., Diamond G.R., Pollack I.P., Langharn M.E. Timolol. A new drug for management of chronic simple glaucoma. Arch. Ophthalmol. 1978; 96: 1003
   PubMed Web of Science ®Google Scholar
• Moss A.P., Ritch R., Hargett N.A., Kuhn A.N., Smith H., Podos S. A comparison of the effects of Timolol and Epinephrine on intraocular pressure. Am. J. Ophthalmol. 1978; 86: 489
   PubMed Web of Science ®Google Scholar
• Zimmerman T.J., Kass M.A., Yablonski M.E., Becker B. Timolol maleate, Efficiency and safety. Arch. Ophthalmol. 1979; 97: 656
   PubMed Web of Science ®Google Scholar
• Obstbaum SA., Galin M.A., Katz I.M. Timolol: Effect on intraocular pressure in chronic open angle glaucoma. Ann. Ophthalmol. 1978; 10: 1347
   PubMed Web of Science ®Google Scholar
• Olson R.J., Bromberg B.B., Zimmerman T.J. Apneic spells associated with Timolol therapy in a neonate. Am. J. Ophthalmol. 1979; 88: 1206
   Google Scholar
• Jones F.L., Ekberg N.L. Exacerbation of asthma by Timolol. N. Engl. J. Med. 1979; 5: 270
   Google Scholar
• Ahmad S. Cardiopulmonary effects of Timolol eye drops. Lancet 1979; 2: 1028
   PubMed Web of Science ®Google Scholar
• Guzman C.A. Exacerbation of bronchorrhea induced by topical Timolol. Am. Rev. Respir. Dis. 1980; 121: 899
   PubMed Web of Science ®Google Scholar
• Jones F.L., Ekberg N.L. Exacerbation of obstructive airway disease by Timolol. J.A.M.A. 1980; 244: 2730
   PubMed Web of Science ®Google Scholar
• Noyes J.H., Chervinsky P. Case report: Exacerbation of asthma by Timolol. Ann. Allergy 1980; 45: 301
   PubMedGoogle Scholar
• Charan N.B., Lakshminarayan S. Pulmonary effects of topical Timolol. Arch. Intern. Med. 1980; 140: 843
   PubMed Web of Science ®Google Scholar
• Schoene R.B., Martin T.R., Charan N.B., French C.L. Timolol-induced bronchospasm in asthmatic bronchitis. J.A.M.A. 1981; 245: 1460
   PubMed Web of Science ®Google Scholar
• Britman N.S. Cardiac effects of topical Timolol. N. Engl. J. Med. 1979; 300: 566
   PubMed Web of Science ®Google Scholar
• Ros F.E., Dake C.L. Timolol eyedrops: Bradycardia or tachycardia?. Doc. Ophthalmol. 1979; 48(2)283–289
   Web of Science ®Google Scholar
• Kim J.V., Smith P.H. Timolol-induced bradycardia. Anesth. Analg. 1980; 59: 301–303
   PubMed Web of Science ®Google Scholar
• Linkewich J.A., Herling I.M. Bradycardia and congestive heart failure associated with ocular Timolol maleate. Am. J. Hosp. Pharmacol. 1981; 38: 699–701
   PubMedGoogle Scholar
• Altus P. Timolol-induced congestive heart failure. South. Med. J. 1981; 74: 88
   PubMed Web of Science ®Google Scholar
• Alvan G., Calissendorf B., Slideman P., Widmark K., Widmark G. Absorption of ocular Timolol. Clin. Pharmacokinet. 1980; 5: 95–100
   PubMed Web of Science ®Google Scholar
• Shell J.W. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 1982; 26: 207
   PubMed Web of Science ®Google Scholar
• Passo M.S., Palmer E.A., Van Buskirk E.M. Plasma Timolol in glaucoma patients. Ophthalmology 1984; 91: 1361–1363
   PubMed Web of Science ®Google Scholar
• Leier C.V., Baker N.D., Weber P.A. Cardiovascular effects of ophthalmic Timolol. Ann. Intern. Med. 1986; 104: 197–199
   PubMed Web of Science ®Google Scholar
• Katz I.M., Hubbard W.A., Getson A.J., Gould L. Intraocular pressure decrease in normal volunteers following Timolol ophthalmic solution. Invest. Ophthalmol. 1976; 15: 489–492
   PubMedGoogle Scholar
• Else O.F., Sorenson H., Edwards I.R. Plasma Timolol levels after oral and intravenous administration. Eur. J. Clin. Pharmacol. 1978; 14: 431–434
   PubMed Web of Science ®Google Scholar
• Bobik A., Jennings G.L., Ashley P., Korner P.I. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration. Eur. J. Clin. Pharmacol. 1979; 16: 243–249
   Web of Science ®Google Scholar
• Rynne M.V. Timolol toxicity: Ophthalmic medication complicating systemic disease. J. Maine Med. Assoc. 1980; 71: 82
   PubMedGoogle Scholar
• Sffrime M.B., Kowenthal D.T., Tobert J.A. Dynamics and kinetics of ophthalmic Timolol. Clin. Pharmacol. Ther. 1975; 18: 278–286
   PubMedGoogle Scholar
• Coppeto J.R. Transient ischaemic attacks and amaurosis fugax from Timolol. Ann. Ophthalmol. 1985; 17: 64–65
   PubMed Web of Science ®Google Scholar
• Treseder A.S., Thomas T. P. L. Sinus arrest due to Timolol eye drops. Br. J. Clin. Pract. 1986; 40: 256–257
   PubMedGoogle Scholar
• Munroe W.P., Rindone J.P., Kershner R.M. Systemic side effects associated with the ophthalmic administration of Timolol. Drug. Intell. Clin. Pharmacol. 1985; 19: 85–86
   PubMedGoogle Scholar
• Hernandez H. Y. H., Cervantes R., Frati A., Hurtado R., McDonald T.O., DeSouza B. Cardiovascular effects of topical glaucoma therapies in normal subjects. J. Toxicol. Cut. Ocular Toxicol. 1983; 2: 99–106
   Web of Science ®Google Scholar
• Doyle W.J., Weber P.A., Meeks R.H. Effect of topical Timolol maleate on exercise performance. Arch. Ophthalmol. 1984; 102: 1517–1518
   PubMed Web of Science ®Google Scholar
• Atkins J.M., Pugh B.R., Timewell R.M. Cardiovascular effects of topical beta-blockers during exercise. Am. J. Ophthalmol. 1985; 99: 173–175
   PubMed Web of Science ®Google Scholar
• Nelson W.L., Fraunfelder E.T., Sills J.M., Arrowsmith J.B., Kuritsky J.N. Adverse respiratory and cardiovascular events attribute to Timolol ophthalmic solution 1978–1985. Am. J. Ophthalmol. 1986; 102: 606–611
   PubMed Web of Science ®Google Scholar
• Ball S. Congestive heart failure from Betaxolol. Arch. Ophthalmol. 1987; 105: 320
   PubMed Web of Science ®Google Scholar
• Nelson W.L., Kuritsky J.N. Early post-marketing surveillance of Betaxolol ophthalmic drops. Am. J. Ophthalmol. 1987; 104: 431
   PubMedGoogle Scholar
• Zabel R.W., MacDonald I.M. Sinus arrest associated with betaxolol ophthalmic drops. Am. J. Ophthalmol. 1987; 104: 431
   PubMed Web of Science ®Google Scholar
• Tattersfield A.E. Beta adreno-receptor antagonists and respiratory disease. J. Cardiovasc. Pharmacol. 1986; 8: 35–39
   Google Scholar
• Fraunfelder F.T., Barker A.F. Respiratory effects of Timolol. N. Engl. J. Med. 1984; 311: 1441
   PubMed Web of Science ®Google Scholar
• Schoene R.B., Abuan T., Ward R.L., Beasly C.H. Effects of topical Betaxolol, Timolol and placebo on pulmonary function in asthmatic bronchitis. Am. J. Ophthalmol. 1984; 97: 86–92
   PubMed Web of Science ®Google Scholar
• Dunn T.L., Gerber M.J., Shew A.S., Femandez E., Iseman M.D., Cherniack R.M. Timolol induced bronchospasm. Utility of Betaxolol as an alternative ocular hypotensive agent in patients with glaucoma. Clin. Res. 1985; 33: 20A
   Google Scholar
• Van Buskirk E.M., Weinreb R.N., Berry D.P., Lustgarten J.S., Podos S.M., Drake M.M. Betaxolol in patients with glaucoma and asthma. Am. J. Ophthalmol. 1986; 101: 531–534
   PubMed Web of Science ®Google Scholar
• Bailey P.L. Timolol and post-operative apnea in neonates and young infants. Anesthesiology 1984; 61: 622
   PubMed Web of Science ®Google Scholar
• Harris L.S., Greenstein S.H., Bloom A.F. Respiratory difficulties with Betaxolol. Am. J. Ophthalmol. 1986; 102: 274–275
   PubMed Web of Science ®Google Scholar
• Van Buskirk E.M., Fraunfelder F.T. Ocular beta-blocker and systemic effects. Am. J. Ophthalmol. 1984; 98: 623–624
   PubMed Web of Science ®Google Scholar
• Fraunfelder F.T., Meyer S.M. Sexual dysfunction secondary to topical ophthalmic Timolol. J.A.M.A. 1985; 253: 3092–3093
   PubMed Web of Science ®Google Scholar
• Core-Smith J.R., Kirk C.A. CNS related side effects with Metoprolol and Atenolol. Eur. J. Clin. Pharmacol. 1985; 28: 69–72, suppl
   PubMed Web of Science ®Google Scholar
• Westerlund A. Central nervous system side effects with hydrophilic and lipophilic beta-blockers. Eur. J. Clin. Phamcol. 1985; 28: 73–76, suppl
   PubMed Web of Science ®Google Scholar
• Orlando R.G. Clinical depression associated with Betaxolol. Am. J. Ophthalmol. 1986; 102: 175
   Google Scholar
• Fraunfelder F.T., Meyer S.M. Drug induced side effects and ocular toxicology. Concepts in Toxicology; Proceedings of the Fifth International Symposium on Drug-Induced Side Effects and Ocular Toxicology, O. Hockwin, F. Homburger. A. G. Karger, Basel 1987; Vol. 4: 30–39
   Google Scholar
• Lynch M.G., Whitson J.T., Brown R.H., Nguyen H., Drake M.M. Topical beta blocker therapy and central nervous system side effects. A preliminary study comparing Betaxolol and Timolol. Arch. Ophthalmol. 1988; 106: 908–911
   PubMed Web of Science ®Google Scholar
• Cohn J.B. A comparative study of the central nervous system effects of Betaxolol versus Timolol. Arch. Ophthalmol. 1989; 107: 633–634
   Web of Science ®Google Scholar
• Vries J.D., Van Der Menve S.A., DeHeer L.J. From Timolol to Betaxolol. Arch. Ophthalmol. 1989; 107: 634
   PubMed Web of Science ®Google Scholar
• Davidorf F.H. Did I tell you the story about Jim, the neurologist?. Contemp. Ophthalm. Forum 1987; 5: 4
   Google Scholar
• Denffer H. Efficacy and tolerance of Metipranolol: Results of a multi-center long-term study. Metipranolol, H.J. Merte. Springer-Verlag, New York 1983; 121–125
   Google Scholar
• Lustgarten J.S. Topical Timolol-induced arthropathy. Am. J. Ophthalmol. 1988; 105: 687–688
   PubMed Web of Science ®Google Scholar
• James O. F. W. The absorption and distribution of drugs in old age. Advanced Geriatric Medicine, F.I. Caird, J.G. Evans. Pitrnan, London 1981
   Google Scholar
• Harte V.J., Timoney R.F. Aspects of the prescribing of drugs for children. Pharm. Intell. 1981; 2(6)132–135
   Google Scholar
• Gladstone G.R., Hordorf A., Gersony W.M. Propranolol administration during pregnancy. Effects on the fetus. J. Pediatr. 1975; 86: 962
   PubMed Web of Science ®Google Scholar
• Blaul G. Me beta blocker wahrend der graviditat. Klin. Monatbl. Augenheilkd. 1981; 179: 128
   PubMedGoogle Scholar
• Samples J.R., Meyer S.M. Use of ophthalmic medications in pregnancy and nursing women. Am. J. Ophthalmol. 1988; 106: 16–623
   Google Scholar
• Lustgarten J.S., Podos S.M. Topical Timolol and the nursing mother. Arch. Ophthalmol. 1983; 101: 1381
   PubMed Web of Science ®Google Scholar
• Sinclair N.I., Bernie J.L. Timolol eye drops and Verapamil—a dangerous combination. Med. J. Aust. 1983; 1: 548
   PubMed Web of Science ®Google Scholar
• Mishra P., Calvey T.N., Williams N.E., Murray G.R. Intraoperative bradycardia and hypotension associated with Timolol and Pilocarpine eye drqs. Br. J. Anaesthesiol. 1983; 55: 897–898
   PubMed Web of Science ®Google Scholar
• Gwynne G.L. Drug interaction. Anaesthesia 1984; 39(3)293
   PubMed Web of Science ®Google Scholar
• Dinai Y., Sharir M., Naveh N., Halkin H. Bradycardia induced by interaction between Quinidine and ophthalmic Timolol. Ann. Intern. Med. 1985; 103(6)890–891
   PubMed Web of Science ®Google Scholar
• Brown R.H., Hotchkiss M.L., Davis E.B. Creating smaller eye drops by reducing eye dropper dimensions. Am. J. Ophthalmol. 1985; 99: 460–464
   PubMed Web of Science ®Google Scholar
• Brown R.H., Lynch M.G. Design of eye dropper tips for topical beta-blocking agents. Am. J. Ophthalmol. 1986; 102: 123–124
   PubMed Web of Science ®Google Scholar
• Petursson G., Cole R., Hanna C. Treatment of glaucoma using minidrops of Clonidine. Arch. Ophthalmol. 1984; 120: 1180–1181
   Google Scholar
• Fraunfelder F.T. Extraocular fluid dynamics. How best to apply topical ocular medication. Trans. Am. Ophthalmol. Soc. 1977; 74: 547
   Google Scholar
• Zimmerman T.J., Kooner K.S., Kandarakis A.S., Ziegler L.P. Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. 1984; 102: 551
   PubMed Web of Science ®Google Scholar
• Huang T.C., Lee D.A. Punctal occlusion and topical medication for glaucoma. Am. J. Ophthalmol. 1989; 107: 151–155
   PubMed Web of Science ®Google Scholar
• Mills K.B., Raines M., Joyce P. A single blind, stratified, randomized, non-crossover trial comparing Carteolol 1% with Timolol 0.25% in the longterm management of glaucoma. Br. J. Clin. Pract. 1987; 41(550)10–12
   Google Scholar
• Brazier D.J., Smith S.E. Ocular and cardiovascular response to topical Carteolol 2% and Timolol 0.5% in healthy volunteers. Br. J. Ophthalmol. 1988; 72: 101–103
   PubMed Web of Science ®Google Scholar